Luma Group is a New York-based multistage biotechnology investment firm founded in 2023 by Joshua Fink, bringing together scientific insight and computation to identify and back breakthrough life sciences companies from discovery through commercialization.
Luma Group invests across the life sciences ecosystem globally, backing biotechnology companies translating breakthrough science into therapies, diagnostics, and medical devices.
The firm's thesis centers on the convergence of biology, chemistry, physics, and artificial intelligence reshaping medicine, supported by LABI, its proprietary AI system for data analysis and breakthrough validation. Luma invests from early-stage discovery through commercialization.
Luma Group closed its debut fund, LumaBio Fund I, at $410M in committed capital, structured as a 15-year investment vehicle.
LPs include a global investor base of financial institutions, sovereign wealth funds, insurance companies, family offices, and ultra-high-net-worth individuals.
The fund has already recorded its first exit, with portfolio company Vaccine Company acquired by Eli Lilly for up to $1.55B.
Leadership
Investment Strategy
Check size of $5M–$20M.
The firm invests from early-stage discovery through commercialization, combining first-principles science partnerships with hands-on industry leadership support and its proprietary AI platform, LABI.
Notable Investments
Themasap Khan — Co-Founder & Partner
themasap@lumagroup.com
Jamie Kasuboski — Partner & Head of Research
jamie@lumagroup.com
Negin Mokhtari — Venture Partner
negin.mokhtari@lumagroup.com
United States
